Innovative Approaches in Glioblastoma Treatment: The Role of Optune in Enhancing Patient Survival
Ashvin Kumar *
Department of Biological Sciences, University of Chicago, Chicago, IL, USA.
Nicholas Truong
Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA.
Rahul Jandial
Department of Neurosurgery, Beckman Research Institute, City of Hope National Cancer Center, Duarte, USA.
*Author to whom correspondence should be addressed.
Abstract
Glioblastoma multiforme (GBM) is the most common form of malignant primary brain and CNS (central nervous system) tumors in adults. Prognosis is generally poor and the current standard for treatment often fails to meet expectations. In recent years, Optune has garnered attention for its novel approach to cancer treatment. Utilizing biophysical principles, Optune employs tumor-treating fields (TTFields) to preferentially disrupt cells undergoing mitosis. In this review, we examine Optune’s current role in progressing cancer treatments through its unique mechanism of action. We consider its future application with other carcinomas and current drawbacks and adoption from a biological and economic standpoint.
Keywords: Optune, Tumor-treating fields (TTFields), GBM (glioblastoma multiforme), temozolomide